Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology [Yahoo! Finance]
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $10.00 price target on the stock.
Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024 [Seeking Alpha]